Skip to main content
. 2021 Apr 14;4:370. doi: 10.1038/s42003-021-01897-6

Fig. 7. PTC596 in vivo treatment affects the growth of KRAS-mutant ADCs.

Fig. 7

a A549 xenografts tumor volumes at treatment termination (vehicle n = 20, red; PTC596 n = 15, blue; PTC208 n = 7, black) normalized to the tumor volume measured at the beginning of treatment. The difference in tumor size at day 21 was statistically significant (p values are indicated). b SPRING plots showing epithelial compartments (green) in vehicle- (n = 3, left panels) versus PTC596-treated tumors (n = 2, right panels). c Pie charts summarizing the epithelial cell proportions in vehicle- (left panels) and PTC596-treated tumors (right panels). d SPRING plots of the 13 clusters in vehicle- (left panel) and PTC596- (right panel) treated tumor samples. e Pie charts summarizing epithelial sub-cluster compositions in vehicle- (left panels) and PTC596- (right panels) treated tumors. f The graph shows the percentage of change in tumor volume measured by MRI at the indicated time points, between PTC596 (n = 7, blue) and vehicle-treated (n = 8, red) groups. Error bars represent SD. P value is indicated.